Flagship presented three posters at the show, including: #AACR2021 poster no. 433: Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation, in partnership with Leap...
Events
UPCOMING EVENTS
- Spatial Biology for Drug Development Summit 2023 | October 11-13, Boston, MA (Exhibitor)
- Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 3-5, San Diego, CA (Booth #716)
- American Society for Hematology (ASH) Annual Meeting & Exposition | December 9-12, San Diego, CA (Booth #3349)
SITC 2020
SITC 2020 November 9-14, 2020As we prepare our poster presentation for the (virtual) Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, we encourage you to register now (members register for FREE!)
Webinar: Digital Pathology with Integrated PD-L1 AI, hosted by Flagship and Gestalt Diagnostics
Join Flagship Biosciences and our partners Gestalt Diagnostics for this informative webinar featuring an overview and discussion of the value of a truly integrated, digital pathology platform, using Artificial Intelligence (AI) to aid in diagnostic decisions! Flagship...
Regulatory Webcast RECORDING: Biomarker Strategies and Implementation in Drug Development
(Recorded live on Tuesday, July 14, 2020) Biomarkers are important tools for successful biopharmaceutical-targeted drug development and regulatory approval. Biomarkers can be diagnostic and/or prognostic, indicative of precision drug targeting. As such, biomarkers are...
Webcast RECORDING: Improving Clinical Trial Outcomes with Tissue Image Analysis: Case Studies
(Recorded live on Thursday, April 16, 2020) Image analysis of histological tissue sections is a fast-growing field that is becoming widely accepted as a research tool for scientists and pathologists, providing quantitative, reproducible data in lieu of varying manual...
AACR Virtual Meeting II – June 22-24, 2020
Flagship was a virtual exhibitor this year during the AACR Virtual Meeting II. Our scientists, led by Chuck Caldwell, shared a new poster during the virtual event.
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
Education and Early CareerJordyn received his Bachelor of Science in Community Health Sciences at the University of Nevada-Reno. Jordyn always wanted to be in the medical field, either in patient care or in medicine. According to an old yearbook, he actually wanted to...
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
Tissue Based Companion Diagnostics in a Regulated Space
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
PUBLICATIONS/POSTERS
Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology conference. We cover image analysis of tumor infiltrating lymphocytes (TIL) and more.
Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in specifically identifying macrophages in PD-L1 stained tissues, but pathologists often have...
Protein Tyrosine Kinase 7 (PTK7) Biomarker Analysis in Patients treated with PF-06647020, a PTK7 Antibody-Drug Conjugate (ADC), in a Phase I Dose Expansion Study
BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing Phase I clinical trial in patients with advanced solid tumors. We hypothesized...